RegulatoryOfficial

CHMP backs AstraZeneca's baxdrostat as Baxfendy for hypertension uncontrolled on two medicines

🇪🇺 EMA · Fri 13 Nov 2026

EMA's human medicines committee adopted a positive opinion on 12 November 2026 for Baxfendy, an aldosterone synthase inhibitor, for adults whose arterial hypertension remains insufficiently controlled.

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on 12 November 2026, recommending a marketing authorisation for Baxfendy (baxdrostat). The applicant is AstraZeneca AB. EMA published the opinion on its website the following day.

The full indication is treatment of adult patients with arterial hypertension insufficiently controlled with at least two antihypertensive medicinal products. Baxfendy will come as 1 mg and 2 mg film-coated tablets. Baxdrostat is classified as an antihypertensive (ATC code C02KN02).

Baxdrostat is a selective inhibitor of human aldosterone synthase. According to EMA, aldosterone contributes to hypertension by promoting renal sodium and water retention, which raises blood volume, and by acting directly on blood vessels to promote dysfunction, inflammation and fibrosis.

The committee said the benefits are clinically relevant and statistically significant reductions in systolic and diastolic blood pressure in patients whose blood pressure stayed high despite at least two blood pressure-lowering medicines. This was seen in randomised, double-blind, placebo-controlled studies. The most common side effect is hyperkalaemia.

A CHMP opinion is a recommendation; the European Commission takes the final decision on the marketing authorisation. EMA says the detailed recommendations for use will appear in the summary of product characteristics (SmPC), to be published in all official EU languages once the Commission has granted authorisation.

What it means for your team

  • Regulatory teams should note that this is a CHMP opinion only; the European Commission decision is still pending, and the SmPC will be published after that.
  • Pharmacovigilance teams should note hyperkalaemia as the most common side effect named by EMA; further risk minimisation detail will depend on the final product information.
  • Market-access teams should note the narrow positioning: adults with hypertension insufficiently controlled on at least two antihypertensives.
  • Product number EMEA/H/C/006597 and the CHMP summary of positive opinion (EMADOC-1829012207-78499) are the reference documents for tracking.

Official source: EMA ↗

Article written by VigiEye from the official source (EMA). AI-assisted; check the source before acting.

More Regulatory All →